The goal of expO and its consortium supporters is to procure tissue samples under standard conditions and perform gene expression analyses on a clinically annotated set of deidentified tumor samples updated with clinical outcomes and release all data into the public domain without intellectual property restriction.
"This publicly accessible gene expression clinical database of patient specimens will fuel and accelerate clinically meaningful and scientifically valid research into better prognostic tests, new diagnostics, targeted therapies, predictive therapeutic strategies and potentially preventative modalities for patients" said IGC’s founder, Daniel Von Hoff, MD, FACP.
IGC has established a uniform system for obtaining and processing tissue samples for molecular characterization studies. Clinical annotation for each tissue sample will enable researchers to form testable clinical hypotheses for use in future treatment decision making. Tissue collection and data dissemination will be conducted in a manner that fully protects patient privacy. Over a three-year period, IGC expects to obtain 2,000 to 3,000 tumor specimens representing a broad spectrum of malignancies and 500-1,000 normal tissues.
expO has exceeded its first-year milestone of collecting consented and clinically annotated tumor biospecimens in a highly standardized format by 65%. This accomplishment puts expO on a projection to exceed its targeted collection and gene expression of 1,900 tumor biosamples over the
Source:International Genomics Consortium